NEW DELHI: Drug makers importing medicines may soon have to pay the government up to five times more to register their products here and get their overseas manufacturing facilities audited by the Indian regulator. The move aims to increase domestic manufacturing of medicines. After a meeting between the Central Drugs Standard Control Organization and industry stakeholders in August, the ministry is once again mulling a hike in fees for several regulatory submissions for foreign drug makers, said two senior health ministry officials. A similar move was suggested in December 2015 as well. “All stakeholders present agreed, in principle, to a hike in fees (as per the 2015 draft notification),” stated a document that ET has viewed. “Members also stressed (the need) to revise fees periodically after three years, instead of 15 years. The proposal for amendment in rules is under process.” Revision of fees is necessary, as rates have not been updated for more tha...
A subsidiary of AR EduX. As Pharmaceutical professionals and an indispensable part of medical sciences, we take it upon ourselves to recondition and fortify the current Pharmaceutical education scenario in society and provide the most relevant information to cure and treat the various Pathophysiological conditions related to human health.